Private Placement

Cogent Biosciences is set for a transformative year, eyeing three FDA submissions and a launch for its lead drug, with a deep pipeline to follow.

A major new partnership is racing to deploy predictive tech, from blood tests to eye scans, to prevent millions of stillbirths in years, not decades.

Moderna CEO Stephane Bancel joins CFS's board, signaling a major push to commercialize fusion energy. Can his vaccine scale-up success crack the code?

TriSalus Life Sciences reports record 53% annual revenue growth, but a closer look reveals a complex financial picture for the oncology innovator.

WindRose and Francisco Partners invest in Avalon, signaling a major shift toward tech-driven management of the multi-billion dollar diagnostic testing market.

IVECO and PlusAI are deploying Level 4 autonomous trucks on a key Spanish freight corridor, heralding a new era for logistics in Southern Europe.

Uniper secures 500,000 tons of certified green ammonia from India's AM Green, forging a new energy axis and fueling Europe's industrial decarbonization.

A minor change in Collective Metals' $1.5M financing deal reveals the high stakes in its hunt for Canadian uranium. Here’s what it means for investors.

Hong Kong's 3E Network completes a $2M financing round, fueling its strategic shift into the competitive global AI infrastructure market.

A novel drug that glues cancer proteins to the cellular trash system has entered human trials, offering new hope for rare diseases like Ewing sarcoma.

A new alliance aims to advance KFRX06, a unique Parkinson's therapy that goes beyond a single target to potentially offer a more comprehensive treatment.

A Texas firm delivered 1.9M tons of carbon removals via ranching, paying farmers millions and showing how soil can be a powerful climate solution.

Major drill results in New Brunswick reveal a rich antimony deposit, a key step in challenging China and Russia's grip on this strategic mineral supply.

With new funding, Major Medical Devices is advancing a novel AAA repair device that uses arm access, promising safer procedures and wider patient eligibility.

Akari Therapeutics is advancing a new class of cancer drugs. Its unique PH1 payload kills tumors and activates the immune system, setting up a pivotal 2026.

With promising data in hard-to-treat cancers, iOnctura's lead drug, roginolisib, is set to make waves at the top healthcare investment forum.

With a key FDA decision looming, Orca Bio's massive new funding aims to commercialize a therapy that could make curative transplants safer for more patients.

With a huge new investment, MEDIPOST is advancing its proven stem cell therapy for knee osteoarthritis into a pivotal Phase III trial in the United States.

With up to $80.8M in new funding, Curis is set to accelerate trials for emavusertib, a promising drug targeting some of the toughest blood cancers.

An expanded partnership aims to create next-gen cancer therapies by combining bispecific antibodies with two distinct drugs to overcome tumor resistance.